Comprehensive CNN and FOX and other media reports, the U.S. White House announced on April 12, the first time the specific drugs defined as "emerging threats," the first on the list is Xylazine and Fentanyl. Rahul Gupta, director of the Office of National Drug Control Policy, said the designation of Fentanyl laced with Xylazine as an emerging threat to the United States is the first time in U.S. history that an administration has declared a drug to be an emerging threat.
Prior to the White House announcement, the federal Drug Enforcement Administration (DEA) also issued a public safety alert on March 20 of this year, stating that "DEA has seized mixtures of Xylazine and Fentanyl in 48 states across the United States; and, Xylazine was detected in 23 percent of Fentanyl powder and 7 percent of Fentanyl pills seized in 2022."
Biotest specializes in POCT and is committed to providing solutions for global drug co-management. Back in 2018 at the beginning of Fentanyl abuse, Biotest launched a rapid Fentanyl detection test. Until early 2023, when the abuse of "zombie drugs" broke out, the market for rapid tests in this field was still blank. In response to this "emerging threat", Biotest has taken a forward-looking perspective, followed the global drug detection trend, and continued to innovate and optimize to launch the Xylazine rapid test to help the global anti-drug prevention cause.
With the principle of immunochromatography, Biotest’s Xylazine and Fentanyl Rapid Test can detect the presence of Xylazine and Fentanyl in human urine, powder or liquid within 5 minutes. With the characteristics of rapid, sensitive and accurate, it not only brings great convenience to drug detection, but also contributes to the international anti-drug cause in China.